Eli Lilly and Company will announce its financial results for the second quarter of 2026 on August 5. The company will hold a conference call at 10 a.m. Eastern time to discuss its performance with investors and the media, accessible via a live webcast on its website. This update is important for investors to understand Lilly's progress in key health areas like diabetes, obesity, Alzheimer's, immune disorders, and cancer treatments. A replay of the call will also be available for later viewing.
Biotech mergers and acquisitions reached $78 billion in the first half of 2026, surpassing the entire 2025 total of $42 billion, driven by several large deals over $5 billion. Despite strong structural drivers like patent expirations and cash reserve...
President Donald Trump announced that generic drugs imported into the US will continue to have zero tariffs for two more years starting August 1, 2024. After this period, tariffs will rise to 100% for one year and then 200% thereafter. The policy aim...
The US announced a phased tariff plan on imported generic drugs starting August 1, 2026, with zero tariffs for two years, followed by a 100% tariff in August 2028 and 200% in 2029. This move aims to encourage generic drugmakers to relocate production...
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the company of misleading advertising for its GLP-1 drugs Zepbound and Mounjaro. Novo claims Lilly's ads use outdated data and unfairly compare Lilly's highest drug doses to lower d...
